ResMed Inc. vs Vanguard Real Estate Index Fund ETF — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Vanguard Real Estate Index Fund ETF trades at $90.65 (market cap $70.80B). The key difference: Vanguard Real Estate Index Fund ETF is far larger — about 2.2× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while Vanguard Real Estate Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Vanguard Real Estate Index Fund ETF for 113 Days on average.
| RMD | VNQ | |
|---|---|---|
Market Cap | $31.89B | $70.80B |
Volume | 618,314 | 6,073,580 |
Sector | Health | — |
52-Week High | $275.96 | $100.95 |
52-Week Low | $182.82 | $87.00 |
Typical Hold Time | 51 Days | 113 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
VNQ trades at $89.35, up 0.74% today but facing bearish technical signals with 14 sell signals versus 5 buy signals. The ETF has declined nearly 10% over the past month amid rising Treasury yields and Federal Reserve rate hikes, eroding its income appeal relative to safer alternatives. Recent institutional buying by State Street Corp and Envestnet suggests some value hunting despite sector headwinds.
Outlook remains challenged by interest rate sensitivity, though contrarian investors see opportunity in discounted REIT valuations. Key risks include continued rate hikes and property oversupply, while potential catalysts include yield stabilization and sector rotation if economic conditions improve.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →